HIV and TB at Jhpiego





Applying science to save lives worldwide

Since 2009, Jhpiego has targeted evidence-based approaches, such as index testing and HIV self-testing to support 19,878,674 people to know their HIV status, including 626,786 people living with HIV and we helped clients link to the prevention and treatment services they needed:

- In the past year we provided antiretroviral therapy services for 184,518
 people with 96% viral load suppression among those with access to viral
 load testing.
- TB preventive treatment for 217,577 people living with HIV on ART.
- 1,593,390 people living with HIV were screened for TB.

Scaling new interventions with fidelity

- Since 2003, Jhpiego has enabled 6,068,010 men to access safe and voluntary medical male circumcision—the most of any implementer.
- Trailblazing PrEP implementation at scale since 2016, supporting 226,561 people to initiate PrEP to date and now piloting online and physical pharmacy models.
- Leading implementation science on the introduction of injectable PrEP and vaginal ring as well as enhanced TB case finding, treatment and prevention.





Serving people in ways that matter to them

- Early adopters of design and demand approaches, we elevate clients as co-designers and decision-makers to offer equitable, respectful, empathetic services for all.
- Immersed in communities, our demand creation and services reach an intersection of underserved across sectors.

Frontier technology that promotes quality

- Machine learning to predict which clients are likely to need enhanced support to stay on ART.
- Social media listening to understand how the people we reach discuss health and health-seeking with peers men, women, adolescents, children and key and vulnerable populations, in conflict settings.
- Duplication detection for confidence in our data quality.



Where we work

